Literature DB >> 23612191

Effect of three drugs against Encephalitozoon cuniculi infection in immunosuppressed mice.

Maria Anete Lallo1, Lidiana F Vidoto da Costa, João Manoel de Castro.   

Abstract

Microsporidia comprise a large group of obligate intracellular parasites. The microsporidian Encephalitozoon cuniculi causes disseminated infection in immunosuppressed patients with HIV, cancer, or transplants and in the elderly. In vivo and in vitro studies on the effectiveness of drugs are controversial. Currently, there is no effective treatment. We tested albendazole, albendazole sulfoxide, metronidazole, and cyclosporine in mice immunosuppressed with cyclophosphamide and inoculated by the intraperitoneal route with 10(7) E. cuniculi spores. One week after experimental inoculation, the mice were treated with albendazole, albendazole sulfoxide, metronidazole, and cyclosporine. Histological and morphometric analyses were performed to compare the treated groups. The state of immunosuppression was evaluated by phenotyping CD4(+) and CD8(+) T cells by flow cytometry. Nontreated mice showed acute disseminated and fatal encephalitozoonosis. The treatment with benzimidazoles significantly reduced infection until 30 days posttreatment (p.t.), but at 60 days p.t., the infection had recurred. Metronidazole decreased infection by a short time, and cyclosporine was not effective. All animals were immunosuppressed by all the experiments, as demonstrated by the low number of CD4(+) and CD8(+) T cells. We conclude that no drug was effective against E. cuniculi, but the benzimidazoles controlled the infection transiently.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23612191      PMCID: PMC3697356          DOI: 10.1128/AAC.00157-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Antimicrosporidial activities of fumagillin, TNP-470, ovalicin, and ovalicin derivatives in vitro and in vivo.

Authors:  Peter J Didier; Jennifer N Phillips; Dorothy J Kuebler; Mohamed Nasr; Paul J Brindley; Mary E Stovall; Lisa C Bowers; E S Didier
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

2.  Encephalitozoonosis in pharmacologically immunosuppressed mice.

Authors:  Maria Anete Lallo; Marisa Porta Miche Hirschfeld
Journal:  Exp Parasitol       Date:  2012-05-22       Impact factor: 2.011

Review 3.  Microsporidiosis: an emerging and opportunistic infection in humans and animals.

Authors:  Elizabeth S Didier
Journal:  Acta Trop       Date:  2005-04       Impact factor: 3.112

Review 4.  Therapeutic strategies for human microsporidia infections.

Authors:  Elizabeth S Didier; Joseph A Maddry; Paul J Brindley; Mary E Stovall; Peter J Didier
Journal:  Expert Rev Anti Infect Ther       Date:  2005-06       Impact factor: 5.091

5.  Calcium and calmodulin antagonists inhibit human malaria parasites (Plasmodium falciparum): implications for drug design.

Authors:  L W Scheibel; P M Colombani; A D Hess; M Aikawa; C T Atkinson; W K Milhous
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

Review 6.  Microsporidiosis: epidemiology, clinical data and therapy.

Authors:  S Anane; H Attouchi
Journal:  Gastroenterol Clin Biol       Date:  2010-08-10

Review 7.  Parasitic infections in solid organ transplant recipients.

Authors:  Patricia Muñoz; Maricela Valerio; Daniel Puga; Emilio Bouza
Journal:  Infect Dis Clin North Am       Date:  2010-06       Impact factor: 5.982

Review 8.  Zoonotic potential of the microsporidia.

Authors:  Alexander Mathis; Rainer Weber; Peter Deplazes
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

9.  Intestinal microsporidiosis with Septata intestinalis in a patient with AIDS--response to albendazole.

Authors:  C Franzen; A Müller; A Schwenk; B Salzberger; G Fätkenheuer; G Mahrle; V Diehl; M Schrappe
Journal:  J Infect       Date:  1995-11       Impact factor: 6.072

10.  In vitro model to assess effect of antimicrobial agents on Encephalitozoon cuniculi.

Authors:  B Beauvais; C Sarfati; S Challier; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

View more
  5 in total

1.  Prevention and treatment of Encephalitozoon cuniculi infection in immunosuppressed rabbits with fenbendazole.

Authors:  S S Abu-Akkada; S S Oda
Journal:  Iran J Vet Res       Date:  2016       Impact factor: 1.376

2.  Encephalitozoon cuniculi Genotype II Concentrates in Inflammation Foci.

Authors:  Klára Brdíčková; Bohumil Sak; Nikola Holubová; Dana Květoňová; Lenka Hlásková; Marta Kicia; Żaneta Kopacz; Martin Kváč
Journal:  J Inflamm Res       Date:  2020-09-25

3.  Encephalitozoon cuniculi Genotype III Evinces a Resistance to Albendazole Treatment in both Immunodeficient and Immunocompetent Mice.

Authors:  Bohumil Sak; Klára Brdíčková; Nikola Holubová; Dana Květoňová; Lenka Hlásková; Martin Kváč
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

Review 4.  A multidisciplinary review about Encephalitozoon cuniculi in a One Health perspective.

Authors:  Tomás Rodrigues Magalhães; Filipe Fontes Pinto; Felisbina Luisa Queiroga
Journal:  Parasitol Res       Date:  2022-07-16       Impact factor: 2.383

5.  In vitro antimicrosporidial activity of gold nanoparticles against Heterosporis saurida.

Authors:  Mona Saleh; Gokhlesh Kumar; Abdel-Azeem Abdel-Baki; Saleh Al-Quraishy; Mansour El-Matbouli
Journal:  BMC Vet Res       Date:  2016-03-03       Impact factor: 2.741

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.